Solid state forms of vemurafenib and vemurafenib salts

Abstract

The present invention provides Vemurafenib salts, particularly Vemurafenib esylate and Vemurafenib choline, and solid state forms thereof and processes for preparing these compounds. The present invention also provides the use of the solid state forms of Vemurafenib and of the Vemurafenib salts for preparing Vemurafenib or other Vemurafenib salts, and solid state forms thereof.

What is claimed is: 
     
         1 . Vemurafenib choline salt. 
     
     
         2 . The Vemurafenib choline salt of  claim 1  wherein the molar ratio between Vemurafenib and choline is about 1:1. 
     
     
         3 . The Vemurafenib choline salt of  claim 1  in solid form. 
     
     
         4 . The Vemurafenib choline salt of  claim 1  in crystalline form. 
     
     
         5 . A pharmaceutical composition comprising the Vemurafenib choline salt according to  claim 1 . 
     
     
         6 . A pharmaceutical formulation comprising the Vemurafenib choline salt according to  claim 1  and at least one pharmaceutically acceptable excipient. 
     
     
         7 . A method for manufacturing a pharmaceutical formulation according to  claim 6  comprising combining a Vemurafenib choline salt according to  claim 1  with at least one pharmaceutically acceptable excipient. 
     
     
         8 . A method of treating a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of the Vemurafenib choline salt according to  claim 1 , the pharmaceutical composition according to  claim 5 , or the pharmaceutical formulation according to  claim 6 . 
     
     
         9 . A process for preparing Vemurafenib comprising preparing a Vemurafenib choline salt according to  claim 1  and converting it to Vemurafenib. 
     
     
         10 . The process according to  claim 10 , wherein the conversion is accomplished by a process comprising acidifying the Vemurafenib choline salt to obtain Vemurafenib.